Eli Lilly sues sellers of unapproved retatrutide in first such lawsuits

Eli Lilly has filed its first lawsuits against sellers accused of offering unapproved copies of retatrutide, the company's experimental weight loss drug, Endpoints News reported on August 1, 2026 ^[1]. Two months later, the company was suing five more companies accused of selling illicit copies of the same drug, according to the Washington Post's Health Brief ^[2].

Endpoints News described the filings as the first lawsuits over a retatrutide "black market" ^[1]. The cases were listed under the publication's law coverage alongside other pharmaceutical litigation ^[1]. The identities of the defendants, the courts where the cases were filed and the damages Lilly is seeking have not been reported in these accounts.

The Washington Post reported on October 9, 2026, that Lilly was suing five additional companies accused of selling illicit copies of retatrutide, and that chief executive Dave Ricks was pressing regulators to do more about such sales ^[2]. The Post described retatrutide as an experimental weight loss drug ^[2]. It has not been approved as a prescription medicine, and the copies at issue in the suits are described as illicit ^[2].

It has not been disclosed how many total lawsuits Lilly has now filed, whether any defendant has responded, or whether Lilly is asking courts to shut down specific websites or sellers. It also has not been reported whether any of the products sold as retatrutide were tested to confirm what they contained.

Why it matters for patients

Retatrutide is not an approved drug, so there is no regulated version that a pharmacy could dispense. Any product marketed under that name is being sold outside the normal supply chain that the Food and Drug Administration oversees for prescription medicines. When a drug has not gone through approval, there is no reviewed manufacturing standard for it, and buyers have no independent way to confirm what a vial or pill actually holds.

The lawsuits target sellers, not buyers. Nothing in the reporting suggests the filings create a legal risk for people who have purchased such products, and nothing in them offers a route to obtain retatrutide legally. People who are interested in the drug and want a supervised source have had to look to clinical trials rather than to online sellers, though the reporting does not describe the current status of Lilly's trials or how patients can enroll.

The cases also signal that drugmakers are willing to use courts, not just warning letters, against sellers of unapproved GLP-1-related products. That matters for anyone who has seen retatrutide offered through social media, messaging apps or loosely regulated websites. Lilly's public pressure on regulators, described by the Post ^[2], suggests the company wants enforcement to widen beyond its own lawsuits.

What happens next

No court dates, hearing schedules or rulings have been reported in either account ^[1][2]. It also has not been disclosed whether Lilly plans further filings against additional sellers. The most recent dated development is the October 9, 2026, report that five more companies had been sued ^[2].